

# Zenbexus™

(iberdomide) capsules

0.75 mg 1 mg



## Welcome to the CELMoDern Era *with ZENBEXUS*

### THE FIRST-EVER CELMoD, A NEW CLASS\* OF TREATMENT FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA

ZENBEXUS is a CELMoD treatment that helps **boost your immune system's ability to fight multiple myeloma**. ZENBEXUS is a prescription medicine used in combination with the medicines daratumumab and hyaluronidase-fihj (injection) and dexamethasone (pill) to treat adults with multiple myeloma who have received at least 1 prior medicine, including a proteasome inhibitor and an immunomodulatory medicine.

\*New class: cereblon modulating protein degrader.  
Actor portrayals.  
ZENBEXUS is approved for adult use only.

#### **WHAT IS ZENBEXUS (iberdomide)?**

ZENBEXUS is a prescription medicine used in combination with the medicines daratumumab and hyaluronidase-fihj and dexamethasone to treat adults with multiple myeloma who have received at least 1 prior medicine, including a proteasome inhibitor and an immunomodulatory medicine. It is not known if ZENBEXUS is safe and effective in children.

ZENBEXUS was approved based on minimal residual disease (MRD) negativity (or no detectable cancer cells). There are ongoing studies to see how well ZENBEXUS works.

#### **SELECT IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNINGS**

ZENBEXUS may cause serious side effects including possible harm to your unborn baby (embryo-fetal toxicity). Females who are pregnant or plan to become pregnant must not take ZENBEXUS. ZENBEXUS is available only through a restricted program called the ZENBEXUS Risk Evaluation and Mitigation Strategy (REMS) Program. ZENBEXUS can cause life-threatening blood clots in your legs (deep vein thrombosis), lungs (pulmonary embolism), and heart or brain that can cause heart attack or stroke (arterial thromboembolic events). See Important Safety Information throughout this brochure and on pages 15-20, including instructions for females who can become pregnant and males whose partner can become pregnant, and more information on blood clots and the REMS program.

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and [U.S. Full Prescribing Information](#) and [Medication Guide](#) at [ZENBEXUS.com](#).

# What do I need to know about ZENBEXUS?

**Zenbexus™**   
(iberdomide) capsules  
0.75 mg 1 mg



ZENBEXUS is a **once-daily pill\*** **you can take at home**, 3 weeks on, 1 week off each 28-day cycle as prescribed.



ZENBEXUS taken along with daratumumab (injection)\* and dexamethasone (pill) made multiple myeloma cells **undetectable for nearly twice as many people compared with DVd.<sup>†</sup>**



Your doctor will **carefully manage your treatment with ZENBEXUS**. If you experience any side effects, tell your doctor immediately. They may adjust your dose or tell you to take a break from treatment.

Because of the risk of harm to an unborn baby, ZENBEXUS is only available through a restricted program called the **ZENBEXUS REMS program**. See Important Safety Information throughout and the **Medication Guide** at [ZENBEXUS.com](http://ZENBEXUS.com) for more information.

\*Taken in combination with dexamethasone (a pill) and daratumumab and hyaluronidase-fihj (an injection given by your doctor). Your doctor may tell you to take ZENBEXUS once every other day if you take certain medicines, or if you have kidney problems and experience side effects.

<sup>†</sup>In a clinical study, 85 out of 207 people (41%) taking ZENBEXUS + daratumumab and hyaluronidase-fihj + dexamethasone (ZDd) were minimal residual disease (MRD) negative with a complete response or better, compared with 44 out of 213 people taking daratumumab and hyaluronidase-fihj + bortezomib + dexamethasone (DVd), after a median follow-up time of 16 months.

**WE OFFER FINANCIAL SUPPORT AND ASSISTANCE FOR PEOPLE TAKING ZENBEXUS.  
LEARN HOW WE CAN HELP ON PAGE 13.**

## **WARNING: RISK TO UNBORN BABIES**

 ZENBEXUS may cause serious side effects, including **harm to an unborn baby**.

 **If you are pregnant, you plan to become pregnant, or your partner plans to become pregnant**, ZENBEXUS may harm your unborn baby.

**If you are female** (sex assigned at birth) and **you are able to become pregnant**:

You **must not be pregnant** and you **must agree to stop sexual activity with a male or must use two highly effective forms of birth control at the same time**, even if you have a history of infertility, unless you have had a hysterectomy:

- for at least 4 weeks before starting ZENBEXUS
- while taking ZENBEXUS
- during any breaks (interruptions) in your treatment with ZENBEXUS
- for at least 4 weeks after stopping ZENBEXUS

You **must have 2 negative pregnancy tests** before you start treatment with ZENBEXUS.

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and U.S. Full Prescribing Information and Medication Guide at [ZENBEXUS.com](http://ZENBEXUS.com).

# WHAT YOU'LL FIND IN THIS BROCHURE

|                                             |         |
|---------------------------------------------|---------|
| <u>How ZENBEXUS works</u>                   | PAGE 4  |
| <u>Results with ZENBEXUS</u>                | PAGE 5  |
| <u>What is MRD?</u>                         | PAGE 6  |
| <u>What to expect while taking ZENBEXUS</u> | PAGE 7  |
| <u>How to take ZENBEXUS</u>                 | PAGE 9  |
| <u>Financial support and assistance</u>     | PAGE 13 |
| <u>ZENBEXUS resources</u>                   | PAGE 14 |

Actor portrayals.

## **WARNING: RISK TO UNBORN BABIES (CONTINUED)**

You will also need pregnancy tests:

- every week for the first 4 weeks of treatment with ZENBEXUS, followed by:
  - every 4 weeks if your menstrual cycle is regular OR
  - every 2 weeks if your menstrual cycle is irregular

If you miss your period or have irregular bleeding, you will need to have a pregnancy test and receive counseling.

**Do not** donate eggs during treatment and for 4 weeks after your last dose of ZENBEXUS.



**Talk to your healthcare team about effective methods of birth control** that are safe to use with ZENBEXUS.



**Call your healthcare provider right away if you become pregnant or think you are pregnant** during treatment with ZENBEXUS.



**Stop taking ZENBEXUS right away if you become pregnant or think you are pregnant** during treatment with ZENBEXUS.

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and U.S. Full Prescribing Information and Medication Guide at [ZENBEXUS.com](https://www.zenbexus.com).

# How ZENBEXUS works


**Zenbexus™**  
(iberdomide) capsules  
0.75 mg 1 mg

## ZENBEXUS IS THE FIRST-EVER CELMoD

ZENBEXUS is a CELMoD treatment that helps **boost your immune system's ability to fight multiple myeloma**. ZENBEXUS is a prescription medicine used in combination with the medicines daratumumab and hyaluronidase-fihj (injection) and dexamethasone (pill) to treat adults with multiple myeloma who have received at least 1 prior medicine, including a proteasome inhibitor and an immunomodulatory medicine.

**ZENBEXUS is designed to work in 3 key ways:**

 IMMUNE CELL    PROTEIN    MYELOMA CELL




### Activates your immune system

ZENBEXUS helps boost the activity of certain cells in your immune system to find and fight myeloma.



### Breaks down proteins

ZENBEXUS helps identify and break down certain proteins that myeloma cells need to survive.



### Contributes to destruction of myeloma cells

Without these proteins, myeloma cells can't grow or survive.

**ZENBEXUS HELPS YOUR BODY ATTACK AND DESTROY MYELOMA CELLS.**

## WARNING: RISK TO UNBORN BABIES (CONTINUED)

**If you are male** (sex assigned at birth) with a female partner who can become pregnant:

ZENBEXUS may pass into human semen.

You should use latex or synthetic condoms during any sexual contact with a partner who is pregnant or able to become pregnant, and for at least 4 weeks after your last dose of ZENBEXUS, even if you have had a successful vasectomy, and you should not donate sperm:

- while taking ZENBEXUS
- for at least 4 weeks after stopping ZENBEXUS




**Call your healthcare provider right away if your partner becomes pregnant** during treatment with ZENBEXUS.

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and U.S. Full Prescribing Information and Medication Guide at [ZENBEXUS.com](https://ZENBEXUS.com).

## Results with ZENBEXUS

**Zenbexus™**   
(iberdomide) capsules  
0.75 mg 1 mg

**~2X** ZENBEXUS + Dd made multiple myeloma cells  
**UNDETECTABLE**  
for nearly **twice as many people\***



In the clinical study, **85 out of 207 people (41%)** taking ZENBEXUS + daratumumab and hyaluronidase-fihj + dexamethasone (ZDd) were **minimal residual disease (MRD) negative with a complete response or better**, compared with **44 out of 213 people (21%)** taking daratumumab and hyaluronidase-fihj + bortezomib + dexamethasone (DVd). This was after a median<sup>†</sup> follow-up time of 16 months.<sup>‡</sup>

Learn more about MRD on [page 6](#).

The **clinical study** included people whose multiple myeloma had come back after treatment (**relapsed**) or stopped responding to their last therapy (**refractory**). 207 people took ZENBEXUS + daratumumab and hyaluronidase-fihj + dexamethasone (or “ZDd”) and 213 people took daratumumab and hyaluronidase-fihj + bortezomib + dexamethasone (or “DVd”).

\*Compared with those taking DVd.

†Median is the middle number in a group of numbers arranged from lowest to highest.

‡The conditional approval of ZENBEXUS is based on MRD negativity (or no detectable cancer cells). There are ongoing studies to see how well ZENBEXUS works.

### **WARNING: RISK TO UNBORN BABIES (CONTINUED)**

#### **If you are breastfeeding or plan to breastfeed:**



Do not breastfeed during treatment with ZENBEXUS.



**Talk to your healthcare team** about the best way to feed your baby during this time.

**Because of the risk of serious side effects, ZENBEXUS is only available through the ZENBEXUS Risk Evaluation and Mitigation Strategy (REMS) Program.**

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and U.S. Full Prescribing Information and Medication Guide at [ZENBEXUS.com](https://ZENBEXUS.com).

# What is MRD?

**Zenbexus™**  
(iberdomide) capsules  
0.75 mg 1 mg



## WHY MEASURE MRD?

Minimal residual disease (MRD) is measured to see if a very small amount of myeloma can be found after achieving complete response or better with treatment (when all signs of cancer have disappeared).



## WHAT IS MRD NEGATIVITY?

If you are MRD negative, it means that **out of every 100,000 cells doctors checked, not one was found to be myeloma**. Even if you have a complete response (CR) and are MRD negative, it's not the same as being cured. There is a chance myeloma can still come back.



## DO I NEED TO BE TESTED FOR MRD?

MRD is typically **only measured in clinical studies**. Since MRD testing is not part of standard multiple myeloma care, your oncologist may not test for it.

## WARNING: RISK TO UNBORN BABIES (CONTINUED)



Before you can take ZENBEXUS, you and your healthcare provider must be enrolled in the ZENBEXUS REMS Program. Your healthcare provider will explain the ZENBEXUS REMS Program to you.

You must:

- Read and agree to all the instructions in the ZENBEXUS REMS.
- Sign the Patient Enrollment Form.

ZENBEXUS is only available through pharmacies that participate in the ZENBEXUS REMS Program. Your healthcare provider will give you information about how to find a participating pharmacy.



**Call the REMS Call Center** at 1-888-423-5436:

- if you or your partner become pregnant while taking ZENBEXUS and your healthcare provider is not available
- to enroll in the pregnancy exposure registry that monitors the outcomes of patients who take ZENBEXUS during pregnancy

Healthcare providers and patients should report all cases of pregnancy to:

- FDA MedWatch at 1-800-FDA-1088, **and**
- REMS Call Center

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and U.S. Full Prescribing Information and Medication Guide at [ZENBEXUS.com](http://ZENBEXUS.com).

# What to expect while taking ZENBEXUS

**Zenbexus™**   
(iberdomide) capsules  
0.75 mg 1 mg

During treatment with ZENBEXUS, side effects may occur. It's important to be mindful, track any changes, and assess how you're feeling.

## POSSIBLE SERIOUS SIDE EFFECTS\*

Severe low white  
blood cell counts  
(neutropenia)

Infections

New cancers  
(secondary cancers)

\*Serious side effects in  $\geq 2\%$  of people included in the study.

## MOST COMMON SIDE EFFECTS

Decreased white blood cell  
counts (neutropenia)

Tiredness

Rash

Decreased white blood cells  
(leukopenia) and lymphocytes  
(lymphopenia)

Muscle and joint pain

Sleep problems such as  
insomnia, restless leg syndrome

Decreased platelets  
(thrombocytopenia)

Pneumonia

Abnormally low  
levels of antibodies  
(hypogammaglobulinemia)

Decreased hemoglobin  
(anemia)

Diarrhea

COVID-19

Upper respiratory infections

Trouble controlling your body  
movements (motor dysfunction)

Constipation

**ALWAYS LET YOUR DOCTOR KNOW RIGHT AWAY IF YOU EXPERIENCE ANY SIDE EFFECTS.**

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and [U.S. Full Prescribing Information](#) and [Medication Guide](#) at [ZENBEXUS.com](#).

# What to expect while taking ZENBEXUS

**Zenbexus™**  
(iberdomide) capsules  
0.75 mg 1 mg

## **ZENBEXUS CAN CAUSE POSSIBLE HARM TO YOUR UNBORN BABY**

Females who are pregnant or plan to become pregnant must not take ZENBEXUS. ZENBEXUS has not been tested in pregnant females and has harmed unborn animals in animal testing.

### **Females who can become pregnant must:**

- Not become pregnant during treatment with ZENBEXUS and for at least 4 weeks after your last dose of ZENBEXUS
- Obtain 2 negative pregnancy tests before starting ZENBEXUS, then weekly for 4 weeks, then every 4 weeks (if you have a regular menstrual cycle) or every 2 weeks (if you have an irregular menstrual cycle). You will need to have a pregnancy test and receive counseling if you miss a menstrual period or experience unusual bleeding
- You must also use two acceptable, highly effective forms of birth control simultaneously during this entire time. Talk with your healthcare provider about acceptable options
- Do not donate eggs during treatment and for 4 weeks after your last dose of ZENBEXUS
- If you become pregnant, stop taking ZENBEXUS immediately and contact your healthcare provider or the **REMS Call Center** at 1-888-423-5436 if your healthcare provider is not available. All pregnancy cases should also be reported to FDA MedWatch at 1-800-FDA-1088. A pregnancy exposure registry is available—call the REMS Call Center to enroll

### **Males:**

- **ZENBEXUS may pass into human semen.** Use a latex or synthetic condom during any sexual contact during your treatment, and for at least 4 weeks after your last dose of ZENBEXUS, even if you had a successful vasectomy
- **Do not** donate sperm during treatment with ZENBEXUS and for 4 weeks after your last dose of ZENBEXUS. Tell your healthcare provider right away if your female partner becomes pregnant

## **ZENBEXUS CAN CAUSE LIFE-THREATENING BLOOD CLOTS**

ZENBEXUS can cause life-threatening blood clots in your legs (deep vein thrombosis), lungs (pulmonary embolism), and heart or brain that can cause heart attack or stroke (arterial thromboembolic events). Your healthcare provider may start you on medicine to help prevent blood clots.

### **Tell your healthcare provider right away if you get any of the following signs and symptoms during treatment:**

- Swelling, pain or tenderness, red or discolored skin on your legs
- Chest pain that may spread to the arms, neck, jaw, back, or stomach
- Sudden shortness of breath, dizziness or lightheadedness
- Vomiting
- Feeling sweaty
- Sudden numbness or weakness in the face, arm, or leg, especially on one side of the body
- Severe headache or confusion
- Problems with vision, speech, or balance

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and U.S. Full Prescribing Information and Medication Guide at [ZENBEXUS.com](http://ZENBEXUS.com).

# How to take ZENBEXUS

**Zenbexus™**   
(iberdomide) capsules  
0.75 mg 1 mg



Actor portrayals.

ZENBEXUS is taken as part of your myeloma care plan along with daratumumab (injection)\* and dexamethasone (pill).

**TAKE ZENBEXUS EXACTLY AS YOUR DOCTOR TELLS YOU TO.**



**ZENBEXUS is an oral pill\***  
you can take at home.



**ZENBEXUS is taken once daily† for 3 weeks in a row, then 1 week off before starting again.**



**ZENBEXUS is taken in combination with daratumumab (injection)\* and dexamethasone (pill).**

\*Taken in combination with dexamethasone (a pill) and daratumumab and hyaluronidase-fihj (an injection given by your doctor).

†Your doctor may tell you to take ZENBEXUS once every other day if you take certain medicines, or if you have kidney problems and experience side effects.

## WARNING: RISK OF BLOOD CLOTS



ZENBEXUS can cause **serious and life-threatening blood clots in the veins of your legs** (deep vein thrombosis), **lungs** (pulmonary embolism), **and in your heart or brain that can cause heart attack or stroke** (arterial thromboembolic events).



Your healthcare provider may start you on medicine to help prevent blood clots if you have certain risk factors.



**Call your healthcare provider right away if you get any of the following signs and symptoms of blood clots** during treatment with ZENBEXUS:

- swelling, pain, or tenderness in your legs
- red or discolored skin on your leg
- chest pain that may spread to the arms, neck, jaw, back, or stomach area
- sudden shortness of breath
- dizziness or lightheadedness
- vomiting
- feeling sweaty
- sudden numbness or weakness in the face, arm, or leg, especially on one side of the body
- severe headache or confusion
- problems with vision, speech, or balance

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and U.S. Full Prescribing Information and Medication Guide at [ZENBEXUS.com](https://ZENBEXUS.com).

# How to take ZENBEXUS (cont'd)

**Zenbexus™**  
(iberdomide) capsules  
0.75 mg 1 mg

## ZENBEXUS IS A PILL YOU CAN TAKE AT HOME

ZENBEXUS is taken as part of your multiple myeloma care plan along with daratumumab and hyaluronidase-fihj (an injection given by your doctor) and dexamethasone (a pill). **The calendar below shows an example of when you might take each treatment in the first 28-day cycle.** If your doctor prescribes ZENBEXUS in combination with daratumumab and dexamethasone, be sure to read the Patient Information that comes with each of those medicines.

Dosing for daratumumab or dexamethasone may change in the following cycles. Take each medicine exactly as your doctor tells you to. Your doctor may tell you to take ZENBEXUS once every other day if you take certain medicines, or if you have kidney problems and experience side effects.

**KEY:**  ZENBEXUS  DARATUMUMAB  DEXAMETHASONE (not actual size of treatments)

| CYCLE 1                                                                                   |                                                                                           |                                                                                           |                                                                                           |                                                                                           |                                                                                             |                                                                                             |
|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| 1<br>    | 2<br>    | 3<br>    | 4<br>    | 5<br>    | 6<br>    | 7<br>    |
| 8<br>   | 9<br>   | 10<br>  | 11<br>  | 12<br>  | 13<br>  | 14<br>  |
| 15<br> | 16<br> | 17<br> | 18<br> | 19<br> | 20<br> | 21<br> |
| 22<br> | 23                                                                                        | 24                                                                                        | 25                                                                                        | 26                                                                                        | 27                                                                                          | 28                                                                                          |



**VISIT [ZENBEXUS.COM/TAKING-ZENBEXUS](https://zenbexus.com/taking-zenbexus) TO SEE WHEN TO TAKE EACH TREATMENT AS YOU CONTINUE YOUR CARE PLAN.**

## WHAT SHOULD I DISCUSS WITH MY HEALTHCARE TEAM BEFORE RECEIVING ZENBEXUS?



**Talk to your healthcare team about all of your medical conditions, including:**

- heart problems (including blood clots, heart attacks, stroke, or other heart problems)
- high cholesterol
- high blood pressure
- smoking
- a current infection
- kidney problems

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and U.S. Full Prescribing Information and Medication Guide at [ZENBEXUS.com](https://zenbexus.com).

# How to take ZENBEXUS (cont'd)

**Zenbexus™**  
(iberdomide) capsules  
0.75 mg 1 mg

## TIPS TO REMEMBER



Take ZENBEXUS with or without food



Swallow ZENBEXUS whole. Don't open, break, or chew ZENBEXUS capsules



Take ZENBEXUS at about the same time every day



If you take too much ZENBEXUS, call your doctor right away

If you miss a dose of ZENBEXUS and it has been less than 12 hours since your regular time, take it as soon as you remember. If it has been more than 12 hours, just skip your missed dose.

**Do not take 2 doses at the same time.**

**Leave ZENBEXUS in the package until you're ready to take your dose.** Don't handle the capsules more than you have to. If a capsule breaks or spills on you, clean up the powder and then wash the area of your body with soap and water.

**ALWAYS TAKE ZENBEXUS EXACTLY AS YOUR DOCTOR TELLS YOU TO.**

## WHAT SHOULD I DISCUSS WITH MY HEALTHCARE TEAM BEFORE RECEIVING ZENBEXUS? (CONTINUED)



**Talk to your healthcare team about all the medicines you are taking, including:**

- prescription medicines
- over-the-counter medicines
- vitamins
- herbal supplements

Certain medicines may affect how ZENBEXUS works or cause side effects.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

## WHAT ARE THE POSSIBLE SIDE EFFECTS OF ZENBEXUS?

### Serious side effects

ZENBEXUS can increase the risk of serious side effects. **A serious side effect** is a side effect that can sometimes become life-threatening and can lead to death. The side effects of ZENBEXUS include:

**Harm to an unborn baby** (embryo-fetal toxicity). If you are pregnant, you plan to become pregnant, or your partner plans to become pregnant, ZENBEXUS may harm your unborn baby.

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and U.S. Full Prescribing Information and Medication Guide at [ZENBEXUS.com](https://www.zenbexus.com).

# How to take ZENBEXUS (cont'd)

**Zenbexus™**  
(iberdomide) capsules  
0.75 mg 1 mg

## WAYS TO WORK ZENBEXUS INTO YOUR DAILY LIFE\*



**Set an alarm** on your phone or a calendar reminder for days you are taking ZENBEXUS. It's a great way to remember to take your medicine.



Decide what time of day to take ZENBEXUS. **Combine it with another part of your routine**, like before brushing your teeth in the morning or after finishing your evening meal.



Keep the pill bottle somewhere easy to remember. **Always store it in the same place.** Avoid storing ZENBEXUS in extreme temperatures.

\*Taken in combination with dexamethasone (a pill) and daratumumab and hyaluronidase-fihj (an injection given by your doctor).

## REFILLING YOUR PRESCRIPTION

You may receive your prescription from a specialty pharmacy, in which case your specialty pharmacy will call you each month to arrange delivery directly to your home. Be sure to save their phone number in your contacts.

**Because of the risk of harm to an unborn baby**, ZENBEXUS is available only through a restricted program called the **ZENBEXUS Risk Evaluation and Mitigation Strategy (REMS)**. Before you can take ZENBEXUS, you and your healthcare provider must be enrolled in ZENBEXUS REMS. Your healthcare provider will explain the ZENBEXUS REMS Program to you and have you sign a Patient Enrollment Form. ZENBEXUS is only available through pharmacies that participate in ZENBEXUS REMS.

**If you have questions about the ZENBEXUS REMS Program, ask your doctor, visit [ZENBEXUSREMS.com](https://ZENBEXUSREMS.com), or call 1-888-423-5436.**



Actor portrayals.

## WHAT ARE THE POSSIBLE SIDE EFFECTS OF ZENBEXUS? (CONTINUED)

**Increased risk of blood clots.** ZENBEXUS can cause serious and life-threatening blood clots in the veins of your legs (deep vein thrombosis), lungs (pulmonary embolism), and in your heart or brain that can cause heart attack or stroke (arterial thromboembolic events). Your healthcare provider may start you on medicine to help prevent blood clots if you have certain risk factors.

**Severe low white blood cell counts (neutropenia).** Your healthcare provider will do blood tests during treatment with ZENBEXUS. Tell your healthcare provider if you have a fever.

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and U.S. Full Prescribing Information and Medication Guide at [ZENBEXUS.com](https://ZENBEXUS.com).

# At Bristol Myers Squibb, we provide support with purpose

**Zenbexus™**   
(iberdomide) capsules  
0.75 mg 1 mg



Actor portrayals.

 **Bristol Myers Squibb®**

**Access Support® >**

Your patient. Our commitment.

Bristol Myers Squibb is committed to helping patients gain access to their prescribed BMS medications. That's why we offer the **BMS Access Support® program**, which provides resources to help patients understand their insurance coverage and find information on sources of financial support, including co-pay assistance for eligible commercially insured patients.

## FOR MORE INFORMATION

Visit [BMSAccessSupport.com](https://BMSAccessSupport.com). You can also talk with your doctor or call BMS Access Support at 1-800-861-0048, 8 AM to 8 PM ET, Monday-Friday.

## WHAT ARE THE POSSIBLE SIDE EFFECTS OF ZENBEXUS? (CONTINUED)

**Infections.** ZENBEXUS can cause serious infections, including life-threatening infections or death. Tell your healthcare provider if you get signs and symptoms of an infection before or during treatment with ZENBEXUS, including fever, chills, or flu-like symptoms.

**New cancers (secondary cancers).** Your healthcare provider will monitor you for new cancers.

### Most common side effects

The most common side effects of ZENBEXUS in combination with the medicines (daratumumab and hyaluronidase-fihj and dexamethasone) are:

- decreased white blood cell count (neutropenia)
- decreased white blood cells (leukopenia) and lymphocytes (lymphopenia)
- decreased platelets (thrombocytopenia)
- decreased hemoglobin (anemia)
- upper respiratory infections
- tiredness
- muscle and joint pain
- pneumonia
- diarrhea
- trouble controlling your body movements (motor dysfunction)
- rash
- sleep problems such as insomnia or restless leg syndrome
- abnormally low levels of antibodies (hypogammaglobulinemia)
- COVID-19
- constipation

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and U.S. Full Prescribing Information and Medication Guide at [ZENBEXUS.com](https://ZENBEXUS.com).



Actor portrayal.



## GET SUPPORT AND STAY UP-TO-DATE

Sign up for CELMoD Central. You'll receive in-depth information, educational materials, and tips for when you or your loved one begin treatment.

Learn more at [ZENBEXUS.com/Sign-Up](https://ZENBEXUS.com/Sign-Up)

## ASK YOUR DOCTOR ABOUT ZENBEXUS

Dealing with multiple myeloma can be difficult. But planning your questions and your goals before your doctor visit is important. It can help you feel organized, heard, and ready for next steps. Visit [ZENBEXUS.com/Resources](https://ZENBEXUS.com/Resources) to get a conversation starter—and see if a CELMoD treatment is right for you or your loved one.

## WHAT ARE THE POSSIBLE SIDE EFFECTS OF ZENBEXUS? (CONTINUED)

These are not all the possible side effects of ZENBEXUS.



**Call your healthcare provider right away** if you have any symptoms of side effects.

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with ZENBEXUS if you have certain side effects.

ZENBEXUS may affect fertility in females and males, which may affect the ability to have children.



**Talk to your healthcare provider** if this is a concern for you.

You are encouraged to report side effects to FDA at 1-800-FDA-1088.

# Important Safety Information

**Zenbexus™**  
(iberdomide) capsules  
0.75 mg 1 mg

## IMPORTANT FACTS ABOUT ZENBEXUS™ (iberdomide)

This is a summary of important information that you need to know about ZENBEXUS. Your healthcare team can work with you to help answer any questions you may have about this medication. **Keep this information in a safe place so you can refer to it before and during your treatment.**

Look out for the following icons as you read:



Talk to your healthcare team



Call a healthcare provider right away



Helpful information to remember

## WHAT IS ZENBEXUS?

ZENBEXUS is a prescription medicine used in combination with other medicines (daratumumab and hyaluronidase-fihj and dexamethasone) to treat adults with **multiple myeloma (MM)**, when:

- ✓ you have tried one or more types of treatment, including a proteasome inhibitor and an immunomodulatory medicine, that have not worked or have stopped working.

It is not known if ZENBEXUS is safe and effective in children.

- i** ZENBEXUS has been approved based on early **minimal residual disease (MRD)** data.

MRD refers to the small number of cancer cells that are left in the body during or after treatment. This data is used to predict how well the treatment has worked.

The use of ZENBEXUS to treat multiple myeloma is still being studied and may be subject to further review to confirm clinical benefit.

## WARNING: RISK TO UNBORN BABIES

- !** ZENBEXUS may cause serious side effects, including **harm to an unborn baby**.

- 🤰** **If you are pregnant, you plan to become pregnant, or your partner plans to become pregnant,** ZENBEXUS may harm your unborn baby.

**If you are female** (sex assigned at birth) and **you are able to become pregnant:**

You **must not be pregnant** and you **must agree to stop sexual activity with a male or must use two highly effective forms of birth control at the same time**, even if you have a history of infertility, unless you have had a hysterectomy:

- for at least 4 weeks before starting ZENBEXUS
- while taking ZENBEXUS
- during any breaks (interruptions) in your treatment with ZENBEXUS
- for at least 4 weeks after stopping ZENBEXUS

You **must have 2 negative pregnancy tests** before you start treatment with ZENBEXUS.

You will also need pregnancy tests:

- every week for the first 4 weeks of treatment with ZENBEXUS, followed by:
  - every 4 weeks if your menstrual cycle is regular OR
  - every 2 weeks if your menstrual cycle is irregular

If you miss your period or have irregular bleeding, you will need to have a pregnancy test and receive counseling.

**Do not** donate eggs during treatment and for 4 weeks after your last dose of ZENBEXUS.

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and U.S. Full Prescribing Information and Medication Guide at [ZENBEXUS.com](https://www.zenbexus.com).

# Important Safety Information (cont'd)

**Zenbexus™**  
(iberdomide) capsules  
0.75 mg 1 mg



**Talk to your healthcare team about effective methods of birth control** that are safe to use with ZENBEXUS.



**Call your healthcare provider right away if you become pregnant or think you are pregnant** during treatment with ZENBEXUS.



**Stop taking ZENBEXUS right away if you become pregnant or think you are pregnant** during treatment with ZENBEXUS.

**If you are male** (sex assigned at birth) with a female partner who can become pregnant:

ZENBEXUS may pass into human semen.

You should use latex or synthetic condoms during any sexual contact with a partner who is pregnant or able to become pregnant, and for at least 4 weeks after your last dose of ZENBEXUS, even if you have had a successful vasectomy, and you should not donate sperm:

- while taking ZENBEXUS
- for at least 4 weeks after stopping ZENBEXUS



**Call your healthcare provider right away if your partner becomes pregnant** during treatment with ZENBEXUS.

**If you are breastfeeding or plan to breastfeed:**



Do not breastfeed during treatment with ZENBEXUS.



**Talk to your healthcare team** about the best way to feed your baby during this time.

**Because of the risk of serious side effects, ZENBEXUS is only available through the ZENBEXUS Risk Evaluation and Mitigation Strategy (REMS) Program.**



Before you can take ZENBEXUS, you and your healthcare provider must be enrolled in the ZENBEXUS REMS Program. Your healthcare provider will explain the ZENBEXUS REMS Program to you.

You must:

- Read and agree to all the instructions in the ZENBEXUS REMS.
- Sign the Patient Enrollment Form.

ZENBEXUS is only available through pharmacies that participate in the ZENBEXUS REMS Program. Your healthcare provider will give you information about how to find a participating pharmacy.

# Important Safety Information (cont'd)

**Zenbexus™**  
(iberdomide) capsules  
0.75 mg 1 mg

**i Call the REMS Call Center** at 1-888-423-5436:

- if you or your partner become pregnant while taking ZENBEXUS and your healthcare provider is not available
- to enroll in the pregnancy exposure registry that monitors the outcomes of patients who take ZENBEXUS during pregnancy

Healthcare providers and patients should report all cases of pregnancy to:

- FDA MedWatch at 1-800-FDA-1088, **and**
- REMS Call Center

## WARNING: RISK OF BLOOD CLOTS



ZENBEXUS can cause **serious and life-threatening blood clots in the veins of your legs** (deep vein thrombosis), **lungs** (pulmonary embolism), **and in your heart or brain that can cause heart attack or stroke** (arterial thromboembolic events).



Your healthcare provider may start you on medicine to help prevent blood clots if you have certain risk factors.



**Call your healthcare provider right away if you get any of the following signs and symptoms of blood clots** during treatment with ZENBEXUS:

- |                                                                            |                                |                                                                                            |
|----------------------------------------------------------------------------|--------------------------------|--------------------------------------------------------------------------------------------|
| • swelling, pain, or tenderness in your legs                               | • sudden shortness of breath   | • sudden numbness or weakness in the face, arm, or leg, especially on one side of the body |
| • red or discolored skin on your leg                                       | • dizziness or lightheadedness | • severe headache or confusion                                                             |
| • chest pain that may spread to the arms, neck, jaw, back, or stomach area | • vomiting                     | • problems with vision, speech, or balance                                                 |
|                                                                            | • feeling sweaty               |                                                                                            |

## WHAT SHOULD I DISCUSS WITH MY HEALTHCARE TEAM BEFORE RECEIVING ZENBEXUS?



**Talk to your healthcare team about all of your medical conditions, including:**

- heart problems (including blood clots, heart attacks, stroke, or other heart problems)
- high cholesterol
- high blood pressure
- smoking
- a current infection
- kidney problems

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and U.S. Full Prescribing Information and Medication Guide at [ZENBEXUS.com](https://ZENBEXUS.com).

# Important Safety Information (cont'd)

**Zenbexus™**  
(iberdomide) capsules  
0.75 mg 1 mg



**Talk to your healthcare team about all the medicines you are taking, including:**

- prescription medicines
- over-the-counter medicines
- vitamins
- herbal supplements

Certain medicines may affect how ZENBEXUS works or cause side effects.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

## WHAT ARE THE POSSIBLE SIDE EFFECTS OF ZENBEXUS?

### Serious side effects

ZENBEXUS can increase the risk of serious side effects. **A serious side effect** is a side effect that can sometimes become life-threatening and can lead to death. The side effects of ZENBEXUS include:

**Harm to an unborn baby** (embryo-fetal toxicity). If you are pregnant, you plan to become pregnant, or your partner plans to become pregnant, ZENBEXUS may harm your unborn baby.

**Increased risk of blood clots.** ZENBEXUS can cause serious and life-threatening blood clots in the veins of your legs (deep vein thrombosis), lungs (pulmonary embolism), and in your heart or brain that can cause heart attack or stroke (arterial thromboembolic events). Your healthcare provider may start you on medicine to help prevent blood clots if you have certain risk factors.

**Severe low white blood cell counts (neutropenia).** Your healthcare provider will do blood tests during treatment with ZENBEXUS. Tell your healthcare provider if you have a fever.

**Infections.** ZENBEXUS can cause serious infections, including life-threatening infections or death. Tell your healthcare provider if you get signs and symptoms of an infection before or during treatment with ZENBEXUS, including fever, chills, or flu-like symptoms.

**New cancers (secondary cancers).** Your healthcare provider will monitor you for new cancers.

### Most common side effects

The most common side effects of ZENBEXUS in combination with the medicines (daratumumab and hyaluronidase-fihj and dexamethasone) are:

- decreased white blood cell count (neutropenia)
- decreased white blood cells (leukopenia) and lymphocytes (lymphopenia)
- decreased platelets (thrombocytopenia)
- decreased hemoglobin (anemia)
- upper respiratory infections
- tiredness
- muscle and joint pain
- pneumonia
- diarrhea
- trouble controlling your body movements (motor dysfunction)
- rash
- sleep problems such as insomnia or restless leg syndrome
- abnormally low levels of antibodies (hypogammaglobulinemia)
- COVID-19
- constipation

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and U.S. Full Prescribing Information and Medication Guide at [ZENBEXUS.com](https://ZENBEXUS.com).

## Important Safety Information (cont'd)

**Zenbexus™**  
(iberdomide) capsules  
0.75 mg 1 mg

These are not all the possible side effects of ZENBEXUS.



**Call your healthcare provider right away** if you have any symptoms of side effects.

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with ZENBEXUS if you have certain side effects.

ZENBEXUS may affect fertility in females and males, which may affect the ability to have children.



**Talk to your healthcare provider** if this is a concern for you.

You are encouraged to report side effects to FDA at 1-800-FDA-1088.

### HOW SHOULD I TAKE ZENBEXUS?

**Take ZENBEXUS exactly as your healthcare provider tells you** and follow all the instructions of the ZENBEXUS REMS program. You will take ZENBEXUS with other medicines (daratumumab and hyaluronidase-fihj and dexamethasone). Your healthcare provider will give you instructions on how to take these other medicines. If you develop certain side effects, your healthcare provider may pause your treatment or decrease your dose. Your healthcare provider may tell you to take ZENBEXUS differently if you take certain other medications.

You will take ZENBEXUS in **treatment cycles that repeat**. Each treatment cycle will last **4 weeks** (28 days).



- **During weeks 1, 2, and 3** (days 1-21): Take ZENBEXUS by mouth, 1 time each day
- **During week 4** (days 22-28): Do not take any ZENBEXUS

- ✓ **Do** take ZENBEXUS with or without food.
- ✓ **Do** take ZENBEXUS once a day.
- ✓ **Do** take ZENBEXUS at about the same time each day, such as morning or evening.\*
- ✓ **Do** take ZENBEXUS capsules whole with water.



\*Setting an alarm or calendar notification is a great way to remember to take medication.

- ✗ **Do not** open, break, or chew ZENBEXUS capsules.
- ✗ **Do not** remove the ZENBEXUS capsule from the bottle until you are ready to take it.
- ✗ **Do not** give ZENBEXUS to other people, even if they have the same symptoms that you have. It may harm them and **may cause birth defects**.
- ✗ **Do not** donate blood while taking ZENBEXUS and for 4 weeks after stopping ZENBEXUS.

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and U.S. Full Prescribing Information and Medication Guide at [ZENBEXUS.com](http://ZENBEXUS.com).

# Important Safety Information (cont'd)

**Zenbexus™**  
(iberdomide) capsules  
0.75 mg 1 mg

**ZENBEXUS is available in two different capsules.** Your healthcare provider will tell you which dose is right for you.



**ZENBEXUS 1 mg** is a capsule with a light-gray cap imprinted with "BMS" in white ink and an ivory body imprinted with "1 mg" in black ink.

OR



**ZENBEXUS 0.75 mg** is a capsule with a light-gray cap imprinted with "BMS" in white ink and a dark-brown body imprinted with "0.75 mg" in white ink.

Note: Images do not represent actual capsule sizes.

## Inactive ingredients:

- **All ZENBEXUS capsules contain:** anhydrous lactose, pregelatinized starch, stearic acid, titanium dioxide, iron oxide black, iron oxide yellow, and hypromellose.
- **The 0.75 mg capsule coating also contains:** iron oxide red.

**i** **The powder inside ZENBEXUS capsules should not come into contact with your skin.** If you touch a broken capsule or if the powder comes into contact with your skin, wash the area of your body right away with soap and water.

## WHAT IF I MISS A DOSE?

**Do not take two doses at the same time.**

If it has been **less than 12 hours** since your regular time:

- **take your missed dose** as soon as you remember
- take your next dose of ZENBEXUS at your regularly scheduled time the next day

If it has been **more than 12 hours** since your regular time:

- **skip your missed dose**
- take your next dose of ZENBEXUS at your regularly scheduled time the next day
- do not take 2 doses at the same time



Call your healthcare provider right away if you take too much ZENBEXUS.




For more information, please see the U.S. Full Prescribing Information, including **Boxed WARNINGS** and Medication Guide for ZENBEXUS. Talk to your healthcare provider for more information about this medication.

Please see Important Safety Information, including Boxed WARNINGS, throughout and on pages 15-20, and U.S. Full Prescribing Information and Medication Guide at [ZENBEXUS.com](http://ZENBEXUS.com).

# Zenbexus™

(iberdomide) capsules

0.75 mg 1 mg



Discover more at [ZENBEXUS.com](https://ZENBEXUS.com)

Actor portrayals.  
ZENBEXUS is approved for adult use only.


#### WHAT IS ZENBEXUS (iberdomide)?

ZENBEXUS is a prescription medicine used in combination with the medicines daratumumab and hyaluronidase-fihj and dexamethasone to treat adults with multiple myeloma who have received at least 1 prior medicine, including a proteasome inhibitor and an immunomodulatory medicine. It is not known if ZENBEXUS is safe and effective in children.

ZENBEXUS was approved based on minimal residual disease (MRD) negativity (or no detectable cancer cells). There are ongoing studies to see how well ZENBEXUS works.

#### SELECT IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNINGS

ZENBEXUS may cause serious side effects including possible harm to your unborn baby (embryo-fetal toxicity). Females who are pregnant or plan to become pregnant must not take ZENBEXUS. ZENBEXUS is available only through a restricted program called the ZENBEXUS Risk Evaluation and Mitigation Strategy (REMS) Program. ZENBEXUS can cause life-threatening blood clots in your legs (deep vein thrombosis), lungs (pulmonary embolism), and heart or brain that can cause heart attack or stroke (arterial thromboembolic events). See Important Safety Information throughout this brochure and on pages 15-20, including instructions for females who can become pregnant and males whose partner can become pregnant, and more information on blood clots and the REMS program.



© 2026 Bristol-Myers Squibb Company.  
ZENBEXUS and its associated logo are trademarks of Celgene Corporation, a Bristol Myers Squibb company.  
All other trademarks are the property of their respective owners. 2070-US-2600029 08/26